Pear Therapeutics raises $80M; finds cost savings of $2,150 per patient with opioid use disorder

By SharpBrains | December 11, 2020

Pear Ther­a­peu­tics rais­es $80M in push for reim­burse­ment (Med­C­i­ty News): Pear Ther­a­peu­tics raised $80 mil­lion in fund­ing, which it plans to use as part of a push for cov­er­age of its dig­i­tal ther­a­peu­tics. The Boston-based com­pa­ny has three FDA-cleared prod­ucts, includ­ing dig­i­tal ther­a­peu­tics for sub­stance use dis­or­der, opi­oid use dis­or­der, and most recent­ly, insomnia.

Read More

The FDA clears Somryst, Pear’s digital therapeutic to treat chronic insomnia

By SharpBrains | March 30, 2020

Pear gets FDA clear­ance for insom­nia ther­a­peu­tic (Med­C­i­ty News): “Pear Ther­a­peu­tics received mar­ket­ing autho­riza­tion for its third prod­uct — a dig­i­tal ther­a­peu­tic intend­ed to treat chron­ic insom­nia. Called Som­ryst, the app is avail­able by pre­scrip­tion only. It con­sists of a nine-week pro­gram that includes cog­ni­tive behav­ioral ther­a­py and restrict­ing sleep to a lim­it­ed win­dow of time

Read More

On Awe, Healthy Eating, Mental Health, Ethical Neurotech, and more

By SharpBrains | October 29, 2019

_____ Time to wrap-up anoth­er very active month with our Sharp­Brains e‑newsletter sum­ma­riz­ing excit­ing devel­op­ments in brain research, health­care and tech­nol­o­gy — plus a cou­ple fun brain teasers to spark curios­i­ty and inno­va­tion :-) New brain research: Brain scans shed light on the brain net­works sup­port­ing Awe For World Men­tal Health Day let’s review how a healthy…

Read More

Novartis dissolves agreement to market Pear Therapeutics’ prescription digital therapeutics for substance/ opioid abuse

By SharpBrains | October 25, 2019

_______________ As San­doz returns mar­ket­ing rights for dig­i­tal ther­a­peu­tics to Pear, what does it mean for co-pro­­mote arrange­ments? (MM&M): “San­doz, the gener­ics divi­sion of Novar­tis, is alter­ing com­mer­cial course, return­ing mar­ket­ing duties for two pre­scrip­tion dig­i­tal ther­a­peu­tics (DTx) back to Pear Ther­a­peu­tics. The move, which some had antic­i­pat­ed, comes 18 months after the two signed…

Read More

Trend: Pharma industry warming up to digital therapeutics

By SharpBrains | August 22, 2019

Dig­i­tal ther­a­peu­tics have poten­tial but com­mer­cial suc­cess unproven (Van­tage): “Devel­op­ing drugs to treat dis­or­ders of the cen­tral ner­vous sys­tem is famous­ly fraught with dif­fi­cul­ty. Sev­er­al com­pa­nies, includ­ing Pear Ther­a­peu­tics and Dthera, are tak­ing a wild­ly dif­fer­ent approach: dig­i­tal ther­a­peu­tics. These are pieces of soft­ware designed to treat dis­ease that are reg­u­lat­ed, pre­scribed and even paid…

Read More

Can digital Cognitive Behavioral Therapy (CBTi) become the universal first-line treatment for insomnia?

By SharpBrains | August 13, 2019

__________ Pear Ther­a­peu­tics’ dig­i­tal insom­nia ther­a­peu­tic will put FDA’s Pre­Cert frame­work through its paces (Mobi­Health­News): “Pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Pear Ther­a­peu­tics announced late last week that it has filed an FDA mar­ket­ing autho­riza­tion for Som­ryst, its dig­i­tal cog­ni­tive behav­ioral ther­a­py for the treat­ment of adults with chron­ic insom­nia and depres­sion. While an approval from the…

Read More